Iguratimod for Sjögren’s syndrome symptoms and safety
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary Sjögren’s syndrome diagnosed using 2016 ACR/EULAR criteria
- You have dry eyes and dry mouth symptoms
- Your blood test shows anti-SSA/Ro-60 antibodies are positive
- Your IgG level is at least 16 g/L
- You haven’t taken hormones, immunosuppressants, biologic medicines, or other study drugs in the last 4 weeks
- If you are able to become pregnant: your pregnancy test is negative and you can use reliable birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
This trial tests an experimental drug, IMVT-1402, in adults with primary Sjogren's disease who have moderate to severe symptoms. The goal is to see if it can reduce disease activity safely.
This study looks at an immune reaction (called anti-Ro/SSA IgE) to see how active primary Sjögren’s disease is. It may help doctors better understand what’s driving symptoms and activity levels over time.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests a new pill called upadacitinib (a JAK inhibitor) for people with active Sjögren's syndrome. It may help reduce dryness, fatigue, and joint pain by calming the immune system.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
Hear when a new Primary Sjögren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.